A decade of bisphosphonate bone complications: What it has taught us about bone physiology

International Journal of Oral and Maxillofacial Implants

Volumn 29, Issue 2, 2014, Pages 247-258

  Marx, Robert E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonate induced osteonecrosis of the jaw; Bisphosphonates; Bone modeling; Bone remodeling; Bone resorption; Osteoblasts; Osteoclasts; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE; BONE NECROSIS; BONE REMODELING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEONECROSIS;

EID: 84902595226     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: 10.11607/jomi.te61     Document Type: Article

References (65)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV infection. Nature 1995;373:123-126.
2. Griesser H, Mak TW. Developmental and functional biology of B and T lymphocytes. In: Canellos GP, Lister TA, Sklar JL (eds). The Lymphomas. Philadelphia: WB Saunders, 1998:19-42.
3. Cotton DJ, Powderly WG. Antiretroviral therapy. In: Powderly WG (ed). Manual oOf HIV Therapeutics. Philadelphia: Lippincott-Raven, 1997:42-49.
4. Hanauer SB, Sandburn WJ, Rutzerts P, Fedorak RN, Lukas M, et al. Human anti-necrosis factor monoclonal antibody (adalimumab) in China's disease: The classic trial. Gastroenterology 2006; 130:323-333.
5. Novartis AG. Aredia. Pamidronate disodium for injection, for intravenous infusion. Product Information Sheet. Basel, Switzerland: Novartis AG, 2004:1.
6. Novartis AG. Zometa: Zoledronic acid injection. Product Information Sheet. 2011. http://www.pharma.us.novartis.com/ product/pi/pdf/reclast.pdf. Accessed 18 November 2012.
7. Merck & Co. Inc. Fosamax (alendronate sodium) tablets and oral solution. Product Information Sheet. 2012. http://www. merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi. pdf. Accessed 18 November 2012.
8. Marx RE, Stern DS (eds). Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. Carol Stream, IL: Quintessence, 2002.
9. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1157.
10. Ruggiero SL, Mekrota B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004;62: 527-534.
11. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4254.
12. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61:1104-1107.
13. Etminan M, Amirzadek K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: A nested case-control study. J Rheumatol 2008 Apr;35(4): 691-695. Epub 2008 Jan 15.
14. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients. J Can Dent Assoc 2011;77:b147.
15. Hess LM, Jeter JM, Benham-Hutchins M, Albert MD. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008;121:475-483.
16. Dimopoulos M, Kastridis E, Anagnostopbilos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Hematologica 2006;91: 968-997.
17. Badros A, Weckel D, Goloubeva O, Rapopirt A, Fentin R, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24: 945-952.
18. Glowacki J. The deceiving appearance of osteoclasts. N Engl J Med 2009;36:80-82.
19. Eslami B, Zhou S, Van Ekeren I, Le Boff MS, Glowacki J. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int 2011 Apr;88:272-280. Epub 2011 Feb 15.
20. Jameson JL, Kasper DL, Faui AS, Braunwald E, Lingo DL, et al. Harrison's Endocrinology. New York: McGraw Hill Medical, 2006:411-414.
21. Boyle W, Simonet W, Lacey P. Osteoclast differentiation and activation. Nature 2003;423:337-341.
22. Hofbauer K, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
23. Hofbauer L, Heufeldes A. Role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-253.
24. Hofbauer L, Kuhne C, Viereck V. The OPG/RANKL/RANK system in metabolic bone disease. J Musculoskelet Neuron Interact 2004;4:268-275.
25. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop 1991; 263:30-48.
26. Wergedal JE, Mohan S, Lundy M, Baylink DJ. Skeletal growth factors and other factors known to be present in bone matrix stimulate proliferation and protein synthesis in human bone cells. J Bone Miner Res 1990;5:179-186.
27. Epstein S. The roles of bone mineral density, bone turnover, and other factors in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005;80:379-388.
28. Riggs L. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203-1204.
29. Bonnick S. Monitoring osteoporosis therapy with bone densitometry: A vital tool or regression toward mediocrity? J Clin Endocrinol Metab 2000;10:343-345.
30. Bone HG, Hosking D, Devogalaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
31. Alonso-Cuello P, Garcia-Franco AL, Guyatt G, Moynihan R. Drugs for preosteoporosis: Prevention or disease mongering? BMJ 2008;336:126-129.
32. Edwards MH, McCrae FC, YoungMia SA. Alendronate-related femoral diaphysis fracture. What should be done to predict and prevent subsequent fracture of the contralateral side. Osteoporos Int 2010;21:701-703.
33. Black DM, Thompson DE, Vauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. J Clin Endocrinol Metab 2000; 85:4118-4124 [erratum 2001 Feb;86:938].
34. Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003;349:423-426.
35. Nevraser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low energy femoral shaft fractures associated with alendronate use. J Orthop Traum 2008;22:346-350.
36. Park-Wyllie LY, Mamdani MM, Juirlink DN, et al. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;36:1728-1737.
37. Schilecher J, Michaelsion K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 36:1728-1737.
38. Atik OS, Suluvova F, Gormeli G, Yildririm A, Ali AK. Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy. Eklem Hastalok Carrahisi 2010;21: 56-59.
39. Adami S, Isaia G, Luisetto G, et al. Osteoporosis treatment and fracture incidence. The ICARO longitudinal study. Osteoporosis Int 2008;19:1219-1223.
40. Gorlin RJ, Cohen MM Jr, Hennekam RCM. Osteopetrosis. In: Gorlin RJ, Cohen MM Jr, Hennekam RCM (eds). Syndromes of the Head and Neck, ed 4. New York: Oxford University Press, 2001:285-289.
41. Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. FDA, Sept. 9, 2011. http://www.fda.gov/downloads/advisory committees/committees meeting materials/drugs/drug safety and risk management advisory committee/UCM 270958.pdf. Accessed 19 November 2012.
42. Glowacki J. Bisphosphonates and bone. Ortho J Harv Med School 2005;7:64-65.
43. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;(suppl 2):566-580.
44. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(suppl):2961-2979.
45. Llasseter KC, Porras AG, Denker A, et al. Pharmocokinetic considerations in determining the terminal half-lives of bisphosphonates. Clin Drug Invest 2005;25:107-114.
46. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws. Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
47. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws. History, Etiology, Prevention, and Treatment. Hanover Park, IL: Quintessence, 2007.
48. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007; 65:2397-2404.
49. Migliorai CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine Position Paper. J Am Dent Assoc 2005;136:1658-1668.
50. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws, ed 2. Hanover Park, IL: Quintessence, 2011.
51. Porras AG, Holland SD, Gerz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;6:316-328.
52. Van Beek ER, Lowck CWGM, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect of early osteoclasts precursors without affecting the osteoclastogenic capacity of osteogenic cells. Bone 2002;30:60-74.
53. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 suppl):2-12.
54. Khosla S, Burr D, Cauley J, et al. Bisphosphonate associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1489.
55. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369-376.
56. Rosen HN, Moses AC, Garber J, et al. Serum CTX. A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103.
57. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross linking telopeptide test in prevention and management and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67: 1167-1173.
58. Kwon YD, Oh JY, Kim DY, Chung DJ, Park YD. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws. Can they be utilized as risk markers? Clin Oral Implants Res 2011 Jan;22:100-105. Epub 2010 Oct 13.
59. Greenspan SL, Parker RA, Fergusin L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long term response to alendronate therapy in representative elderly women; A randomized clinical trial. J Bone Miner Res 1998;13:1431-1438.
60. Dodson TB. CTX and its role in managing patients exposed to oral bisphosphonates letter to editor. J Oral Maxillofac Surg 2010; 68:487-494.
61. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): A randomized trial. JAMA 2006;294: 2927-2938.
62. Feher R, Koivunemi A, Koivunemi M, et al. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 2010 Jan;46:203-207. Epub 2009 Oct 24.
63. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, micro damage accumulation, and biochemical properties following 1 year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39:872-879.
64. Gourion-Arsiguaud SG, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogenicity. Bone 2010 Mar; 46:666-672. Epub 2009 Nov 17.
65. Triplett RG, Nevins M, Marx RE, et al. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J Oral Maxillofac Surg 2009;67:1947-1960.